This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • Aflibercept (AF) for age-related macular degeneration (ARMD): four-year outcomes of a ‘’treat-and-extend’ (T&E) regimen with exit-strategy

Aflibercept (AF) for age-related macular degeneration (ARMD): four-year outcomes of a ‘’treat-and-extend’ (T&E) regimen with exit-strategy
Reviewed by Jonathan Chan

3 October 2022 | Jonathan Chan | EYE - Vitreo-Retinal | Neovascularisation, Retina, Vitreous
Share This

This is a retrospective observational study of 82 patients, between 2014 to 2016 from Switzerland of treatment-naive patients with nARMD, treated with AF, with specific T&E protocol without a loading phase and predefined exit criteria and patients were observed three monthly. Best-corrected visual acuity (BCVA) increased from (mean) 51.9 ETDRS letters at baseline to 63.7 at one year, 61.7 at two years, 61.4 at three years and 58.5 at four years (p=0.22). Central field thickness decreased significantly from (mean) 387.5um at baseline, to 289um at four years (p<0.00001). Twenty-eight (35%) patients reached exit strategy and on three monthly observation only. The authors concluded that their cohort on functional outcome is comparable to large studies.

Aflibercept for age-related macular degeneration: 4-year outcomes of a ‘treat-and-extend’ regimen with exit-strategy.
Jaggi D, Nagamany T, Ebneter A, et al.
BRITISH JOURNAL OF OPHTHALMOLOGY
2022;106(2):246-50.
Share This
CONTRIBUTOR
Jonathan Chan

Royal Hallamshire Hospital, Sheffield, UK.

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency